HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

SCMP: SUCAMPO PHARMACEUTICALS CL A - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

SUCAMPO PHARMACEUTICALS CL A (NASD)
SCMP 6.55 -0.28 (-4.10%) Vol.  56,702 15:59 ET

Zacks Rank: N/A - Not Rated

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 6.32 - 6.84
52wk Low - High 2.75 - 6.84
Avg Volume 39,389
Industry MED-DRUGS
Market Cap 286.05 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. N/A
EPS Last Year -0.64
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
N/A
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 09/06/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
SUCAMPO PHARMACEUTICALS CL A SCMP N/A
ASTELLAS PHARMA ALPMY 1
SALIX PHARM-LTD SLXP 1
SPECTRUM PHARMA SPPI 1
Top Peer Analysis Zacks Premium
See all MED-DRUGS Peers

BROKERAGE RECOMMENDATIONS
Current ABR N/A
ABR (Last Week) N/A
# of Recs in ABR N/A
Average Target Price N/A
Rank in Industry 171 out of 92
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate SCMP?
Buy
Sell
Find out what the Zacks Community
thinks of SCMP at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR SCMP
Zacks Equity Research: Report for SCMP
Sep 06, 2010
:
More Zacks Commentary
NEWS
Sucampo Announces Webcast of Its Presentation at the 14th Annual BIO CEO + Investor Conference
Feb 09, 2012
Sucampo and Takeda's Phase III OBD trial meets primary endpoint
Feb 07, 2012
Sucampo Pharmaceuticals Up 40.6% Since SmarTrend Uptrend Call (SCMP)
Feb 03, 2012
Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD)
Feb 02, 2012
Sucampo announces conclusion of arbitration hearing
Dec 30, 2011
Sucampo Pharmaceuticals, Inc. (SCMP) Corporate Event Announcement Notice
Dec 22, 2011
Sucampo Reports Conclusion of Arbitration Hearing
Dec 22, 2011
Sucampo Pharma Americas names vice president of pharmacology and toxicology
Dec 15, 2011
More News
EARNINGS ESTIMATES
  This Quarter
N/A
Next Quarter
N/A
This Year
N/A
Next Year
N/A
Average Estimate N/A N/A N/A N/A
Number of Estimates N/A N/A N/A N/A
Low Estimates N/A N/A N/A N/A
High Estimate N/A N/A N/A N/A
Year Ago EPS N/A N/A N/A N/A
EPS Growth N/A% N/A% N/A% N/A%

More Estimates

COMPANY DESCRIPTION
Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.

Full Company Report
FINANCIALS
EPS TTM -.64
Sales 61.87
Net Income -26.32
Price/Earnings N/A
Price/Book 7.95
Price/Cash Flow N/A
Price/Sales 5.41


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research